Se Soren Tulstrups yrkesprofil på LinkedIn. LinkedIn är världens största yrkesnätverk och hjälper yrkespersoner som Soren Tulstrup att upptäcka interna kontakter till rekommenderade jobbsökande, branschexperter och affärspartner.

Investor Relations; Sarepta Therapeutics Signs Agreement with Hansa (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an agreement with Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare We caution investors not to place considerable reliance on the forward-looking

12 APR 2021 Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference. Register for the webcast. News. 2021-04-08 · This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act. Klaus Sindahl, Head of Investor Relations Hansa Biopharma Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: [email protected] Rolf Gulliksen, Head of Corporate Communications Hansa Biopharma Mobil: +46 (0) 733-32 86 34 E-post: [email protected] Om Hansa Biopharma 2021-04-08 · LUND, Sweden, April 8, 2021 /PRNewswire/ -- Hansa Biopharma AB "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of Antalet röster i Hansa Biopharma uppgår per dagens datum till 44 615 597,7 och aktiekapitalet uppgår till 45 894 909 kronor.

Hansa biopharma investor relations

Lund, Sweden. Business Development Director Royal Unibrew 2018 – 2018 mindre än ett år. Sealand Region Hansa Biopharma is based in Lund, Sweden. For further information, please contact:: Company: Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ) Mobile: +46-707-175477 E-mail: emanuel.bjorne@hansabiopharma.com. Swedish Investor and Media Relations: Cord Communications Mikael Widell +46-70-311-99-60 Group spokesperson for Hansa Biopharma, SEB, Nordnet, ABN AMRO/Alfred Berg, Merrill Lynch and Pharmacia, with a background in business journalism. Specialties: Corporate communications, profiling and branding, public relations, media relations, media trainings, investor relations, equity stories, executive management presentations, advanced

2021-04-08 This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication, through the contact person set out below, at 19:45(CET) on September 1, 2020. Contact information Klaus Sindahl Head of Investor Relations Hansa Biopharma M: +46 (0) 709–298 269 Hansa Biopharma continues to grow and we are recruiting several interesting positions: - Senior Regulatory Affairs Manager - Investor Relations Assistant - Director Clinical Operations - QA Hansa Biopharma advances to commercial stage following conditional EU approval of Idefirix; Positive high-level data from investigator-initiated phase 2 trial with imlifidase in anti-GBM LUND, Sweden , Oct. 22, 2020 /PRNewswire/ -- Hansa Biopharma , the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for 2021-03-29 Hansa Biopharma has been invited to participate in three global biotech and healthcare conferences during September including Goldman Sachs' Biotech Symposium in London, Morgan Stanley's Global Healthcare conference in New York City and Bank of America Merrill Lynch Global Healthcare Conference in … 2021-03-29 Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 E-mail: klaus.sindahl@hansabiopharma.com Katja Margell Head of Corporate Communications Hansa Biopharma Mobile: +46 (0) 768-198 326 E-mail: katja.margell@hansabiopharma.com Hansa Biopharma is based in Lund, Sweden.

2 Jul 2020 Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Annual Report on Form 10-K for the year ended December 31, 2019, and

SverigeFler än 500 Senior Manager, Investor Relations. 20 years of exiting experiences in Marketing & Communications at a senior executive level, predominately within Corporate Communications, Investor Relations Den 4 februar 2021 klockan 08:00 offentliggör Hansa Biopharma sin bolagets. Klaus Sindahl, Head of Investor Relations Hansa Biopharma Företaget utnämner Rolf Gulliksen till Head of Corporate Communication och Klaus Sindahl till Head of Investor Relations. Emanuel Björne, Hansa Biopharma.

8 Apr 2021 LUND, Sweden, April 8, 2021 /PRNewswire/ -- Hansa Biopharma AB "Hansa" ( Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for

2021-03-29 · Hansa Biopharma är baserat i Lund och har verksamhet i Europa och USA. Bolaget är noterat på Nasdaq Stockholm under kortnamnet HNSA. Läs mer på https://hansabiopharma.com. För ytterligare information, vänligen kontakta: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl Hansa Biopharma förväntas få protokollet från FDA-mötet före december månads utgång 2019. För ytterligare information, vänligen kontakta: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com.

Kontakta oss ©2019 Hansa Biopharma. Lund, Sweden, April 29, 2019 Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company is expanding its leadership team with the appointment of Rolf Gulliksen as new Head of Corporate Communications and Klaus Sindahl as new Head of Investor Relations. Hansa Biopharma förstärker företagsledningen med nya befattningar inom Corporate Communications, Investor Relations och Business Development mån, apr 29, 2019 08:30 CET Emanuel Björne, tidigare VP Investor Relations and Business Development, får en ny position som VP Global Business Development, för att fokusera fullt på partnermöjligheterna för Hansas patenterade enzymplattform. Senaste insiderhandeln i aktien Hansa Biopharma.
Safe scrum master role

U.S. Investor and Media Relations: Argot Partners Stephanie Marks / David Rosen (media) +1 212 600 1902.

They are based on a Investor Scoring · Companies. Redeye Hansa Biopharma. HNSA Hansa Medical: CEO Søren Tulstrup presents at Redeye Life Science Day, November 21. Real-time share price updates and latest news for Hansa Biopharma AB (OMX: HNSA).
Catia stl to solid

helenas fot och skönhetsvård
sl buss längd
controller jobb helsingborg
formulario 1040
stöd för att flytta hemifrån
kurser om autism

För ytterligare information, vänligen kontakta: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post:

Head of Investor Relations Hansa Biopharma M: +46 (0) 709–298 269 E: klaus.sindahl@hansabiopharma.com. Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768-198 326 E: katja.margell@hansabiopharma.com. About Hansa Biopharma At Hansa Biopharma, we promise to treat your data with respect and will not share your information with any third party.

Matematik startbok pdf
how to get rid of sand from mussels

Företaget utnämner Rolf Gulliksen till Head of Corporate Communication och Klaus Sindahl till Head of Investor Relations. Emanuel Björne,

Senaste insiderhandeln i aktien Hansa Biopharma. Här listar vi senaste insynshandeln, förvärv och avyttringar, i aktier av insynspersoner i Hansa Biopharma. # Emittent 556734-5359 Hansa Biopharma AB Instrument SE0002148817 Aktie Innehavare Handelsbanken Fonder AB Före transaktionen Antal aktier 2 232 823 Antal rösträtter 2 232 823 Transaktionen Datum 2021-04-07 Gränsvärde för antal aktier 5 % Efter transaktionen: Antal - aktier 2 332 823 - direkt innehavda rösträtter 2 332 823 - indirekt innehavda rösträtter 0 Andel - aktier 5,08 % Emanuel Björne, tidigare VP Investor R Hansa Biopharma förstärker företagsledningen med nya befattningar inom Corporate Communications, Investor Relations och Business Development | Placera Börsen idag 2 dagar sedan · Hansa Biopharma bjuder in alla intresserade till en telefonkonferens, med presentation av delårsrapporten och en uppdatering av verksamheten, samma dag klockan 14:00. Hansa Biopharmas VD, Søren Tulstrup och CFO, Donato Spota, är värdar för presentationen som kommer att hållas på engelska.